Skip to main content
SpringerLink
Log in

Extensionphase der SELECT-Studie bestätigt die Daclizumab-Sicherheitsdaten

Multiple Sklerose: Monoklonaler IL-2-Antikörper in der Langzeittherapie

  • journal club
  • Published:
InFo Neurologie & Psychiatrie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  • Giovannoni G, Gold R, Selmaj K et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicenter, randomised, double-blind extension trial. Lancet Neurol 2014; 13: 472–81

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Neurologie und Palliativmedizin Köln-Merheim, Köln-Merheim, Deutschland

    Volker Limmroth (Chefarzt)

Authors
  1. Volker Limmroth
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Volker Limmroth.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Limmroth, V. Extensionphase der SELECT-Studie bestätigt die Daclizumab-Sicherheitsdaten. InFo Neurologie 16, 20 (2014). https://doi.org/10.1007/s15005-014-0971-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15005-014-0971-7

Search

Navigation